Single cholesterol drug dose after stent for heart outcomes
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a single dose of a cholesterol-lowering drug called a PCSK9 inhibitor can improve heart outcomes after a stent procedure. If you recently had a stent and the imaging showed significant plaque, this may help reduce future risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have coronary artery disease, which includes silent ischemia, stable angina, or acute coronary syndrome (unstable angina or heart attack).
- You had a coronary stent procedure (percutaneous coronary intervention) that used a special imaging test (NIRS-IVUS).
- The imaging must show a certain level of fatty buildup (maxLCBI4mm ≥ 200) in the treated artery.
- You do not have cardiogenic shock or very unstable blood pressure in the last day.
- You are expected to live at least one more year and can sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This trial looks at whether stronger cholesterol-lowering medicine can reduce the risk of future heart problems in people who already have a stent. It focuses on people who still have other mildly narrowed spots in their arteries.
This trial compares different LDL cholesterol targets to find the best level for people at very high risk after a heart stent procedure. It tests whether aiming for a lower cholesterol goal improves outcomes.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.